Journal of clinical and experimental hematopathology : JCEH最新文献_第5页

RHOA G17V mutation analysis redirecting diagnosis: nodal T-follicular helper cell lymphoma with classic Hodgkin lymphoma feature. RHOA G17V突变分析重新诊断：淋巴结t滤泡辅助细胞淋巴瘤伴经典霍奇金淋巴瘤特征。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-01-01 DOI: 10.3960/jslrt.26002

Rio Yamada, Midori Filiz Nishimura, Asami Nishikori, Takuya Fukumi, Kumiko Ohsawa, Shuji Momose, Yasuharu Sato

{"title":"RHOA G17V mutation analysis redirecting diagnosis: nodal T-follicular helper cell lymphoma with classic Hodgkin lymphoma feature.","authors":"Rio Yamada, Midori Filiz Nishimura, Asami Nishikori, Takuya Fukumi, Kumiko Ohsawa, Shuji Momose, Yasuharu Sato","doi":"10.3960/jslrt.26002","DOIUrl":"10.3960/jslrt.26002","url":null,"abstract":"Nodal T-follicular helper cell lymphoma (nTFHL) may present with Hodgkin/Reed-Sternberg (HRS)-like cells and can morphologically mimic classic Hodgkin lymphoma (CHL), although these entities are usually distinguishable. We report an unusual case showing marked morphologic and molecular overlap with CHL, creating a diagnostic challenge but ultimately considered biologically consistent with nTFHL.An 81-year-old woman presented with stage IV disease involving the bone marrow and markedly elevated serum soluble interleukin-2 receptor levels. Excisional lymph node biopsy revealed scattered HRS cells in a T-cell-rich background, with strong CD30 and PD-L1 expression and weak PAX5 positivity, findings consistent with CHL. Fluorescence in situ hybridization demonstrated copy-number alterations at the 9p24.1 locus in HRS cells, further supporting molecular features characteristic of CHL.However, the presence of two T-follicular helper markers, detection of the RHOA p.Gly17Val (G17V) mutation, and oligoclonal T-cell receptor rearrangements with shared peaks in lymph node and bone marrow indicated an underlying nTFHL. The differential therapeutic response also supported a diagnosis of nTFHL, which could not have been established on morphology alone.In this case, although the HRS cells displayed morphological, immunophenotypic, and molecular features highly suggestive of CHL, the biological nature of the lesion was consistent with nTFHL. Compared with previously reported cases of nTFHL with HRS-like cells, this case more closely resembled CHL and may represent a distinct subset best described as \"nTFHL with CHL features,\" a concept warranting greater recognition among pathologists and clinicians.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"66 2","pages":"122-129"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy. 在CD19 car - t细胞治疗后，活检证实炎性肺混浊模仿淋巴瘤复发。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-01-01 DOI: 10.3960/jslrt.26035

Kazuki Okuhiro, Takumi Nishikawa, Yosuke Kodama, Manami Iwanaga, Takami Haruyama, Oju Katayama, Shuhei Honda, Yui Moroga, Kuniko Takano, Haruto Nishida, Masao Ogata

{"title":"Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy.","authors":"Kazuki Okuhiro, Takumi Nishikawa, Yosuke Kodama, Manami Iwanaga, Takami Haruyama, Oju Katayama, Shuhei Honda, Yui Moroga, Kuniko Takano, Haruto Nishida, Masao Ogata","doi":"10.3960/jslrt.26035","DOIUrl":"https://doi.org/10.3960/jslrt.26035","url":null,"abstract":"Pulmonary lesions that newly emerge after chimeric antigen receptor T-cell therapy may raise immediate concern for lymphoma relapse, especially when they occur at sites of prior disease involvement. We report a patient with refractory diffuse large B-cell lymphoma who developed newly apparent or re-enlarged FDG-avid pulmonary opacities four months after axicabtagene ciloleucel infusion. The lesions appeared at or near prior pulmonary lymphoma-suspected sites, strongly suggesting recurrence. However, transbronchial lung biopsy showed organizing pneumonia-like inflammatory changes with Masson bodies, CD3-positive T-cell infiltration, and no evidence of lymphoma involvement by multiple B-cell markers. Because the patient remained clinically stable and relapse was not supported histologically, systemic corticosteroids and salvage chemotherapy were withheld. The biopsied lesion and the remaining pulmonary opacities regressed spontaneously during follow-up, and complete remission was maintained. This case illustrates that organizing pneumonia-like inflammatory lesions may arise at prior lymphoma-suspected pulmonary sites after CAR-T-cell therapy and closely mimic pulmonary relapse on FDG-PET/CT. When new FDG-avid pulmonary lesions arise after CAR-T-cell therapy, particularly at prior lymphoma sites, tissue confirmation is essential to avoid misdiagnosis and unnecessary treatment escalation.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"66 3","pages":"266-271"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solitary plasmacytoma of maxilla with Epstein Barr virus: A case report and literature review. 上颌孤立性浆细胞瘤伴eb病毒1例并文献复习。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-10-30 DOI: 10.3960/jslrt.25033

Chiho Hiraga, Saki Ishikawa, Takayoshi Kikuchi, Taiki Suzuki, Kazuhiko Hashimoto, Keisuke Tanaka, Kimihiro Matsumoto, Takeshi Nomura

{"title":"Solitary plasmacytoma of maxilla with Epstein Barr virus: A case report and literature review.","authors":"Chiho Hiraga, Saki Ishikawa, Takayoshi Kikuchi, Taiki Suzuki, Kazuhiko Hashimoto, Keisuke Tanaka, Kimihiro Matsumoto, Takeshi Nomura","doi":"10.3960/jslrt.25033","DOIUrl":"10.3960/jslrt.25033","url":null,"abstract":"Solitary plasmacytoma (SP) of the bone is a localized neoplasm of plasma cells that can involve the jaw. Epstein-Barr virus (EBV)-positive SP has been documented in immunocompetent individuals; however, its clinicopathological features and prognostic implications remain to be fully clarified. We report a case of EBV-positive SP of the maxilla in a 74-year-old partially edentulous man who presented with swelling in the left posterior maxilla. The lesion measured approximately 30 mm and was covered by intact mucosa. Histopathological examination and systemic evaluation confirmed EBV-positive SP localized to the maxilla. The patient initially received radiotherapy without effect. Subsequently, chemotherapy with ixazomib, lenalidomide, and dexamethasone was administered, resulting in a complete response. No local recurrence was observed after 2 years and 6 months of follow-up. This case highlights the potential for chemotherapy in managing radiotherapy-resistant EBV-positive SP. Further studies are warranted to better understand the pathogenesis and treatment strategies for this rare condition.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"291-297"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triple-hit TdT-positive high-grade B-cell lymphoma mimicking B-lymphoblastic lymphoma and exhibiting immunophenotypic change at relapse. 模拟b淋巴母细胞淋巴瘤的三击tdt阳性高级别b细胞淋巴瘤，复发时表现出免疫表型改变。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-10-30 DOI: 10.3960/jslrt.25030

Akio Saito, Atsushi Isoda, Yukie Terasaki, Hirono Iriuchishima, Masahiro Mihara, Tsukasa Suzuki, Morio Matsumoto, Kennosuke Karube

{"title":"Triple-hit TdT-positive high-grade B-cell lymphoma mimicking B-lymphoblastic lymphoma and exhibiting immunophenotypic change at relapse.","authors":"Akio Saito, Atsushi Isoda, Yukie Terasaki, Hirono Iriuchishima, Masahiro Mihara, Tsukasa Suzuki, Morio Matsumoto, Kennosuke Karube","doi":"10.3960/jslrt.25030","DOIUrl":"10.3960/jslrt.25030","url":null,"abstract":"Terminal deoxynucleotidyl transferase (TdT)-positive high-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements (\"double/triple-hit\" lymphoma) is a rare, aggressive malignancy that often mimics B-lymphoblastic lymphoma (B-LBL), making accurate diagnosis challenging but clinically critical. We report the case of a 63-year-old female with triple-hit HGBCL involving the duodenum, initially presenting with blastoid morphology and a B-LBL-like immunophenotype: TdT(+), CD10(+), CD20(-), BCL6(-), and CD45dim. However, negativity for CD34 and other features inconsistent with B-LBL, such as MUM-1 positivity and cytoplasmic immunoglobulin expression, were also present. Fluorescence in situ hybridization confirmed MYC, BCL2, and BCL6 rearrangements. Despite an initial response to the hyper-CVAD/MA regimen, the patient subsequently relapsed. Relapse biopsies confirmed persistent triple-hit status and clonal identity via IgH gene rearrangement analysis. Unexpectedly, however, the immunophenotype at relapse had changed significantly, with tumor cells becoming TdT(-), CD20(+), and BCL6(+), while remaining CD10(+). Ultimately, the patient died of the disease despite receiving salvage therapies. To our knowledge, this is the first reported case of TdT-positive HGBCL demonstrating loss of TdT expression alongside other immunophenotypic changes at relapse. This case highlights the potential for significant phenotypic change in this rare HGBCL subtype and the importance of comprehensive immunophenotypic and genetic analysis at both diagnosis and relapse for accurate classification and management, particularly in distinguishing it from B-LBL.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"283-290"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spindle-cell variant of diffuse large B-cell lymphoma in the uterine cervix: a case report and literature review. 宫颈弥漫性大b细胞淋巴瘤梭形细胞变异型1例报告并文献复习。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-11-28 DOI: 10.3960/jslrt.25051

Ayaka Ikemoto, Tomoko Uchiyama, Maiko Takeda, Hirokazu Nakamine, Akihiko Yoshizawa

引用次数: 0

Mixed-phenotype acute leukemia with trilineage differentiation presenting as a non-leukemic mediastinal tumor. 混合表型急性白血病三期分化表现为非白血病纵隔肿瘤。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-10-30 DOI: 10.3960/jslrt.25045

Satoshi Ichikawa, Maya Yamato, Shusuke Hatta, Koichi Onodera, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

{"title":"Mixed-phenotype acute leukemia with trilineage differentiation presenting as a non-leukemic mediastinal tumor.","authors":"Satoshi Ichikawa, Maya Yamato, Shusuke Hatta, Koichi Onodera, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae","doi":"10.3960/jslrt.25045","DOIUrl":"10.3960/jslrt.25045","url":null,"abstract":"Mixed-phenotype acute leukemia (MPAL) is an uncommon hematological malignancy, and cases exhibiting trilineage differentiation are extraordinarily rare. Here, we report the case of a 63-year-old male patient who presented with severe dyspnea secondary to a massive anterior mediastinal mass and pleural effusion, in the absence of detectable abnormal cells in the peripheral blood. Immunophenotypic analysis of pleural fluid and tumor biopsy revealed an unprecedented trilineage phenotype with concurrent expression of T-lymphoid (cytoplasmic CD3+ and CD7+), B-lymphoid (CD19+ and CD22+), myeloid (cytoplasmic MPO+ and CD33+) markers, along with stem cell (CD34+ and HLA-DR+), and lymphoblastic (TdT+) markers. B-lineage commitment was further confirmed by immunoglobulin heavy chain gene rearrangement. These findings established a diagnosis of T/B/myeloid triphenotypic MPAL presenting as an aleukemic disease with minimal bone marrow infiltration (<1%). Initial treatment with acute myeloid leukemia-directed induction therapy (daunorubicin plus cytarabine) proved refractory. However, the hyperCVAD regimen, which is an acute lymphoblastic leukemia (ALL)-directed approach, achieved a complete metabolic response. Subsequent consolidation with cord blood transplantation resulted in durable remission lasting 2 years before a late relapse, which occurred in the mediastinal region. This is the first reported case of non-leukemic, triphenotypic MPAL presenting as a primary mediastinal tumor, highlighting the diagnostic complexity and therapeutic challenges associated with this rare malignancy. Based on our experience, intensive ALL-directed chemotherapy followed by allogeneic stem cell transplantation may offer an effective therapeutic strategy for this exceptionally rare clinical entity.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"298-304"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary large B-cell lymphoma of the central nervous system mimicking inflammatory myelitis at initial presentation. 原发性中枢神经系统大b细胞淋巴瘤，最初表现为炎性脊髓炎。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-11-28 DOI: 10.3960/jslrt.25046

Satoshi Ichikawa, Katsuki Imanishi, Hikaru Kumagai, Shunsuke Hatta, Yoko Okitsu, Masahiro Kobayashi, Narumi Okajima, Dai Ichikawa, Fumiyoshi Fujishima, Junichi Kameoka, Tomonori Ishii

{"title":"Primary large B-cell lymphoma of the central nervous system mimicking inflammatory myelitis at initial presentation.","authors":"Satoshi Ichikawa, Katsuki Imanishi, Hikaru Kumagai, Shunsuke Hatta, Yoko Okitsu, Masahiro Kobayashi, Narumi Okajima, Dai Ichikawa, Fumiyoshi Fujishima, Junichi Kameoka, Tomonori Ishii","doi":"10.3960/jslrt.25046","DOIUrl":"10.3960/jslrt.25046","url":null,"abstract":"Primary central nervous system large B-cell lymphoma (PCNS-LBCL) is a rare extranodal non-Hodgkin lymphoma that typically affects the brain parenchyma. Spinal cord involvement as an initial manifestation is extremely uncommon and poses considerable diagnostic challenges, often mimicking inflammatory demyelinating diseases. We report the case of a man in his late 50s who initially presented with steroid-responsive cervical myelitis, resulting in a provisional diagnosis of multiple sclerosis. Despite treatment with corticosteroids and ofatumumab, the patient experienced neurological deterioration and developed cerebellar lesions. Stereotactic brain biopsy confirmed PCNS-LBCL. Although the initial spinal lesion may have represented a definite lymphoma, it was also considered a sentinel lesion, a non-neoplastic inflammatory precursor occasionally observed in PCNSL. This case highlights the diagnostic complexity of PCNS-LBCL presenting with isolated spinal involvement and steroid responsiveness, both of which may delay appropriate treatment. Notably, cerebrospinal fluid analysis at the time of initial presentation of spinal lesions revealed elevated interleukin-10 levels, which declined substantially following chemotherapy, correlating with clinical improvement. Clinicians should maintain a high index of suspicion for central nervous system lymphoma in cases of relapsing myelitis unresponsive to conventional immunotherapy and consider timely biopsy when clinically feasible. Heightened awareness of sentinel lesions may facilitate early recognition and improve outcomes in patients with PCNSL.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"305-311"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma. 成人t细胞白血病/淋巴瘤中CD30与异常淋巴细胞的病理生物学联系

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-10-30 DOI: 10.3960/jslrt.25041

Ryouichi Horie, Mariko Watanabe, Reiko Furuta, Koji Miyazaki, Toshiki Watabnabe

{"title":"Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma.","authors":"Ryouichi Horie, Mariko Watanabe, Reiko Furuta, Koji Miyazaki, Toshiki Watabnabe","doi":"10.3960/jslrt.25041","DOIUrl":"10.3960/jslrt.25041","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATLL) is a T-cell malignancy with poor prognosis caused by human T-cell leukemia virus type 1 (HTLV-1). ATLL is characterized by the emergence of abnormal lymphocytes, represented by the so called \"flower cell\". However, the mechanisms by which these cells contribute to tumorigenic processes associated with HTLV-1 infection are not well understood. Recent reports have suggested that CD30, tumor necrosis factor receptor superfamily 8 plays a role in the generation of these abnormal lymphocytes, providing insight into the involvement of CD30 in the tumorigenic process of HTLV-1-infected cells. Since CD30 can be targeted with brentuximab vedotin (BV), an anti-CD30 antibody linked with monomethyl auristatin E, a tubulin toxin, it is essential to gain a deeper understanding of the functions of CD30 in HTLV-1-infected cells in order to develop effective strategies for treating and preventing ATLL. This review describes the current understanding of how CD30 impacts the development of ATLL in cells infected with HTLV-1, with a specific emphasis on the connection between CD30 and the generation of abnormal lymphocytes.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"238-246"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma. 嵌合抗原受体t细胞和双特异性抗体治疗多发性骨髓瘤的进展和未来展望。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-12-24 Epub Date: 2025-11-28 DOI: 10.3960/jslrt.25038

Tomotaka Suzuki, Shinsuke Iida

{"title":"Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma.","authors":"Tomotaka Suzuki, Shinsuke Iida","doi":"10.3960/jslrt.25038","DOIUrl":"10.3960/jslrt.25038","url":null,"abstract":"The advent of T-cell-redirecting therapies has considerably reshaped the treatment landscape for relapsed/refractory multiple myeloma (RRMM), particularly in patients with triple-class exposed or refractory disease. Chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs), which primarily target B-cell maturation antigen (BCMA), have shown remarkable efficacy in pivotal trials and real-world settings. More recently, G protein-coupled receptor class C group 5 member D-targeted agents have emerged as promising options, particularly for patients who relapse after undergoing BCMA-directed therapy. CAR T-cell therapies can induce deep and durable responses with the potential for long-term remission. However, their use is limited because of manufacturing delays, center certification requirements, and severe toxicity risks. BsAbs offer the advantage of being off-the-shelf, enabling immediate treatment initiation and generally manageable safety profiles, making them the preferred option for frail patients or those with rapidly progressing disease. Nevertheless, continuous dosing and cumulative immunosuppression remain a clinical challenge. Although no direct comparative trials exist between CAR T-cell therapies and BsAbs, each modality has distinct advantages and limitations. Treatment decisions should be individualized based on disease characteristics, patient conditions, and institutional capabilities. Future directions include integrating these agents into earlier lines of therapy, developing novel targets, and exploring multi-antigen strategies to overcome antigen escape. As this field rapidly evolves, real-world evidence and personalized treatment approaches will become critical for optimizing outcomes in patients with RRMM. This review provides an up-to-date summary of the current T-cell-redirecting therapies, including their clinical profiles and safety considerations.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"225-237"},"PeriodicalIF":1.4,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. 在CLL和MCL中，BTK抑制剂作为一种独立于BTK特异性或剂量的一类效应，可以有效地损害血小板聚集。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-09-28 Epub Date: 2025-07-30 DOI: 10.3960/jslrt.25028

Kensuke Kojima, Shinichiro Watanabe, Akari Takeuchi, Naoka Kunisawa, Shohei Yoshida

{"title":"BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL.","authors":"Kensuke Kojima, Shinichiro Watanabe, Akari Takeuchi, Naoka Kunisawa, Shohei Yoshida","doi":"10.3960/jslrt.25028","DOIUrl":"10.3960/jslrt.25028","url":null,"abstract":"BTK inhibitors (BTKi) are established standards of care for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL); however, their use has been associated with an increased risk of bleeding. We investigated whether BTKi impaired platelet aggregation and adhesion in a drug- or dose-dependent manner in patients with CLL and MCL who received ibrutinib, acalabrutinib, or pirtobrutinib. Treatment with BTKi significantly inhibited 2 µg/mL collagen-induced platelet aggregation (CIPA) by 82.1±7.3% (P < 0.0001) in maximum aggregation rates, with levels independent of BTK selectivity and the applied dose. This inhibitory effect was more potent than that of acetylsalicylic acid (aspirin, 100 mg daily) (P < 0.0001). BTKi did not significantly affect adenosine diphosphate- or ristocetin-induced aggregation. The first-generation BTKi ibrutinib but not the newer BTKi acalabrutinib or pirtobrutinib, impairs platelet adhesion, possibly owing to the different inhibitory profiles to SRC family kinases. Our findings have two clinical implications. First, because BTKi treatment inhibits CIPA as a class effect, independent of drug specificity or dose, measuring CIPA levels alone may not help physicians predict near-future bleeding complications. Although the sample size was small, our results suggest the potential of impaired platelet adhesion as a candidate biomarker for estimating bleeding risk in patients receiving BTKi. Second, in BTKi-treated patients requiring anti-platelet agents, BTKi dose reduction may be considered, irrespective of BTK selectivity of the drug or whether aspirin or a P2Y12 receptor inhibitor is used.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"174-179"},"PeriodicalIF":1.4,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12598729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0